Neogenomics (NEO) Asset Writedowns and Impairment (2010 - 2025)

Neogenomics (NEO) has reported Asset Writedowns and Impairment for 12 consecutive years, with $7.1 million the latest figure, recorded in Q3 2025.

• Asset Writedowns and Impairment for Q3 2025 came in at $7.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $15.3 million (up 2269.92% YoY), and the FY2024 annual result was $500000.0, down 70.59% from the prior year.
• Asset Writedowns and Impairment was $7.1 million for Q3 2025 at Neogenomics, down from $8.2 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $8.2 million in Q2 2025 and troughed at -$3000.0 in Q4 2023.
• Average Asset Writedowns and Impairment over 4 years is $2.0 million, with a median of $718000.0 recorded in 2022.
• Year-over-year, Asset Writedowns and Impairment tumbled 100.42% in 2023 and jumped 16766.67% in 2024.
• Over 4 years, Asset Writedowns and Impairment stood at $718000.0 in 2022, then sank by 100.42% to -$3000.0 in 2023, then surged by 16766.67% to $500000.0 in 2024, then surged by 1317.2% to $7.1 million in 2025.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $7.1 million in Q3 2025, $8.2 million in Q2 2025, and $500000.0 in Q4 2024.